Cite
Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial
MLA
Shepherd, F. A., et al. Adjuvant Erlotinib (E) versus Placebo (P) in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) with Tumors Carrying EGFR-Sensitizing Mutations from the RADIANT Trial. Jan. 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....570b7bba44f6b0295f14b64535b5ad89&authtype=sso&custid=ns315887.
APA
Shepherd, F. A., Altorki, N. K., Eberhardt, W., O’Brien, M., Spigel, D. R., Crino, L., Tsai, C. M., Kim, J. H., Cho, E. K., Szczesna, A., Burghuber, O., Hoffman, P. C., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Richardson, F. C., … Tarceva Radiant Investigator Grp. (2014). Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial.
Chicago
Shepherd, F. A., N. K. Altorki, Wilfried Eberhardt, Mary O’Brien, D. R. Spigel, L. Crino, C. M. Tsai, et al. 2014. “Adjuvant Erlotinib (E) versus Placebo (P) in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) with Tumors Carrying EGFR-Sensitizing Mutations from the RADIANT Trial,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....570b7bba44f6b0295f14b64535b5ad89&authtype=sso&custid=ns315887.